The company focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis and cellular stress pathways for therapeutic use in cancer and neurodegenerative diseases. They collaborate with the National Cancer Institute and leading academic institutions to advance VCP/p97 inhibitors for cancer and neurodegenerative disease. Their lead drug development candidate, CB-5339, is a potent, oral, selective, second-generation inhibitor of VCP/p97, which addresses the limitations of earlier compounds, and they are launching a Phase 1 clinical study in acute myeloid leukemia (AML).